PCRX
Pacira BioSciences, Inc.
$22.75
+0.35%
$892.0M
No data for this timeframe.
Vol
Market Cap$892.0M
Cap SizeSmall Cap
Analyst ConsensusBuy (69%)
Inst. Holders8 funds
Inst. Value$241.4M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 9S
Insider Net $-$1.3M
SEC Reports9
Press Releases3
Recent Activity
Jun 5, 2026
SEC
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominee
DEFA14A — Impact 6/10
Jun 4, 2026
SEC
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, value
144 — Impact 2/10
Jun 4, 2026
Insider
WILLIAMS KRISTEN sold 10,259 shares
Chief Administrative Officer @ $22.27 ($228.5K)
Jun 3, 2026
Insider
SLONIN JONATHAN sold 4,728 shares
Chief Medical Officer @ $22.32 ($105.5K)
Jun 3, 2026
Insider
RIKER LAUREN sold 3,187 shares
Senior Vice President, Finance @ $22.32 ($71.1K)
Jun 1, 2026
SEC
Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FOR all three of Pacir
DEFA14A — Impact 5/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
451,852 shares ($11.7M)
Inst.
FMR LLC — TRIM
73,896 shares ($1.9M)
Price Targets
$29.29
+28.7% upside
Strong Buy
Current $22.75
Low $23.00
Median $27.00
High $38.00
7 analysts
$23.00
$38.00
Analyst Ratings
3Strong Buy
6Buy
3Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 1, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| May 1, 2026 | Needham | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.65 ▼ -8.1% | $0.52 — $0.76 | -12% YoY | 7 |
| Next Q | $0.77 ▲ +10.7% | $0.64 — $0.87 | 9% YoY | 7 |
| Current FY | $2.88 ▲ +9.3% | $2.74 — $2.98 | 9% YoY | 7 |
| Next FY | $3.64 ▲ +3.8% | $3.18 — $4.01 | 27% YoY | 7 |
Latest Reports
MIXED
DEFA14A
6/10
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominee
Jun 5, 2026
NEUTRAL
144
2/10
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, value
Jun 4, 2026
MIXED
Press
7/10
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meetin
May 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $124.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $48.8M | — |
| MORGAN STANLEY | $30.9M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $17.5M | NEW |
| TWO SIGMA INVESTMENTS, LP | $11.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | WILLIAMS KRISTEN | SELL | $228.5K |
| Jun 3, 2026 | SLONIN JONATHAN | F | $105.5K |
| Jun 3, 2026 | RIKER LAUREN | F | $71.1K |
| Jun 3, 2026 | WILLIAMS KRISTEN | F | $190.3K |
| Apr 23, 2026 | Cross Shawn | M | $212.9K |
8 institutional holders with $241.4M total value (9,328,943 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,812,955 | $124.6M | 51.6% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,884,001 | $48.8M | 20.2% | — |
| 3 | MORGAN STANLEY | 1,192,594 | $30.9M | 12.8% | TRIM -30.8% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 676,352 | $17.5M | 7.3% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 451,852 | $11.7M | 4.8% | ADD +93.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 184,807 | $4.8M | 2.0% | TRIM -46.1% |
| 7 | FMR LLC | 73,896 | $1.9M | 0.8% | TRIM -27.4% |
| 8 | WELLS FARGO & COMPANY/MN | 52,486 | $1.4M | 0.6% | ADD +41.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 232,994 | 451,852 | +93.9% | $11.7M | 2025-Q4 |
| FMR LLC | TRIM | 101,824 | 73,896 | -27.4% | $1.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 37,180 | 52,486 | +41.2% | $1.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 106,842 | 232,994 | +118.1% | $6.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 296,150 | 159,494 | -46.1% | $4.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 102,980 | 37,180 | -63.9% | $958.1K | 2025-Q3 |
| UBS Group AG | DOUBLED | 421,832 | 1,028,889 | +143.9% | $24.6M | 2025-Q2 |
| FMR LLC | TRIM | 146,160 | 92,680 | -36.6% | $2.2M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 93,587 | 1,364,935 | +1358.5% | $33.9M | 2025-Q1 |
| UBS Group AG | TRIM | 1,374,789 | 421,832 | -69.3% | $10.5M | 2025-Q1 |
| FMR LLC | ADD | 79,371 | 146,160 | +84.1% | $3.6M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 33,724 | 103,684 | +207.4% | $2.6M | 2025-Q1 |
| NORGES BANK | EXIT | 127,655 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 190,755 | 1,374,789 | +620.7% | $25.9M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,595,889 | 1,104,774 | -30.8% | $20.8M | 2024-Q4 |
| NORGES BANK | TRIM | 269,304 | 127,655 | -52.6% | $2.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 583,733 | 93,587 | -84.0% | $1.8M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 516,165 | 1,595,889 | +209.2% | $24.0M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 431,897 | — | $6.5M | 2024-Q3 |
8 unique insiders with 9 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | WILLIAMS KRISTEN | Chief Administrative Officer | SELL | 10,259 | $22.27 | $228.5K |
| Jun 3, 2026 | SLONIN JONATHAN | Chief Medical Officer | F | 4,728 | $22.32 | $105.5K |
| Jun 3, 2026 | RIKER LAUREN | Senior Vice President, Finance | F | 3,187 | $22.32 | $71.1K |
| Jun 3, 2026 | WILLIAMS KRISTEN | Chief Administrative Officer | F | 8,528 | $22.32 | $190.3K |
| Apr 23, 2026 | Cross Shawn | Chief Financial Officer | M | 12,941 | $16.45 | $212.9K |
| Apr 23, 2026 | Cross Shawn | Chief Financial Officer | SELL | 12,941 | $25.16 | $325.6K |
| Apr 23, 2026 | Cross Shawn | Chief Financial Officer | M | 12,941 | $0.00 | $0.00 |
| Apr 22, 2026 | Cross Shawn | Chief Financial Officer | M | 1,500 | $16.45 | $24.7K |
| Apr 22, 2026 | Cross Shawn | Chief Financial Officer | SELL | 1,500 | $25.01 | $37.5K |
| Apr 22, 2026 | Cross Shawn | Chief Financial Officer | M | 1,500 | $0.00 | $0.00 |
| Apr 21, 2026 | Cross Shawn | Chief Financial Officer | M | 2,845 | $16.45 | $46.8K |
| Apr 21, 2026 | Cross Shawn | Chief Financial Officer | SELL | 2,845 | $25.01 | $71.2K |
| Apr 21, 2026 | Cross Shawn | Chief Financial Officer | M | 2,845 | $0.00 | $0.00 |
| Apr 20, 2026 | Cross Shawn | Chief Financial Officer | M | 7,714 | $16.45 | $126.9K |
| Apr 20, 2026 | Cross Shawn | Chief Financial Officer | SELL | 7,714 | $25.14 | $193.9K |
| Apr 20, 2026 | Cross Shawn | Chief Financial Officer | M | 7,714 | $0.00 | $0.00 |
| Mar 17, 2026 | SLONIN JONATHAN | Chief Medical Officer | SELL | 3,261 | $22.82 | $74.4K |
| Mar 17, 2026 | Froimson Mark | Director | SELL | 500 | $21.81 | $10.9K |
| Feb 11, 2026 | Cross Shawn | Chief Financial Officer | A | 49,091 | $0.00 | $0.00 |
| Feb 11, 2026 | SLONIN JONATHAN | Chief Medical Officer | A | 54,546 | $0.00 | $0.00 |
| Feb 11, 2026 | WILLIAMS KRISTEN | Chief Administrative Officer | A | 54,546 | $0.00 | $0.00 |
| Feb 11, 2026 | Teehan Brendan | Chief Commercial Officer | A | 51,714 | $0.00 | $0.00 |
| Feb 11, 2026 | RIKER LAUREN | Senior Vice President, Finance | A | 19,273 | $0.00 | $0.00 |
| Feb 11, 2026 | Lee Frank D. | Chief Executive Officer | A | 261,818 | $0.00 | $0.00 |
| Feb 2, 2026 | RIKER LAUREN | Senior Vice President, Finance | SELL | 4,000 | $20.81 | $83.2K |
| Feb 2, 2026 | WILLIAMS KRISTEN | Chief Administrative Officer | SELL | 13,137 | $20.53 | $269.7K |
| Jan 30, 2026 | SLONIN JONATHAN | Chief Medical Officer | F | 6,168 | $20.54 | $126.7K |
| Jan 30, 2026 | RIKER LAUREN | Senior Vice President, Finance | F | 2,751 | $20.54 | $56.5K |
| Jan 30, 2026 | WILLIAMS KRISTEN | Chief Administrative Officer | F | 17,134 | $20.54 | $351.9K |
| Jan 30, 2026 | Teehan Brendan | Chief Commercial Officer | F | 5,182 | $20.54 | $106.4K |
| Jan 30, 2026 | Lee Frank D. | Chief Executive Officer | F | 41,488 | $20.54 | $852.2K |
| Jun 11, 2025 | Kronenfeld Mark A. | Director | A | 6,163 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 5 mixed, 4 neutral. Avg impact: 4.8/10.
MIXED
DEFA14A
6/10
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's th
Jun 5, 2026
NEUTRAL
144
2/10
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of
Jun 4, 2026
NEUTRAL
DEFA14A
5/10
Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FO
Jun 1, 2026
MIXED
DEFA14A
5/10
Pacira BioSciences issued a DEFA14A letter to stockholders ahead of its June 9, 2026 Annual Meeting,
May 27, 2026
MIXED
DEFA14A
6/10
Pacira BioSciences issued a press release defending its intellectual property strategy against activ
May 26, 2026
MIXED
DEFA14A
6/10
Pacira BioSciences filed additional definitive proxy soliciting materials (DEFA14A) urging stockhold
May 20, 2026
NEUTRAL
8-K
4/10
Pacira BioSciences reported Q1 2026 revenue of $177.4M (+5% YoY) and GAAP EPS of $0.07, down from $0
Apr 30, 2026
MIXED
PREC14A
6/10
Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.
Apr 17, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable. This DEFA14A filing for P
Mar 11, 2026
MIXED
7/10
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the
May 20, 2026
BULLISH
7/10
Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint r
Apr 13, 2026
NEUTRAL
4/10
Pacira BioSciences responded to an activist investor, DOMA Perpetual Capital Management, which has n
Mar 11, 2026
Current analyst consensus: Buy (69% buy). Based on 13 analysts: 3 strong buy, 6 buy, 3 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$29.29 mean target
+28.7% upside
Strong Buy (3.00)
$23.00 Low
$38.00 High
| Metric | Value |
|---|---|
| Current Price | $22.75 |
| Target Low | $23.00 |
| Target Mean | $29.29 |
| Target Median | $27.00 |
| Target High | $38.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.65 | $0.52 | $0.76 | -12.1% | -8.1% | 1↑ 6↓ | $0.2B | 5.2% | 7 |
| Next Q 2026-09-30 |
$0.77 | $0.64 | $0.87 | 9.5% | +10.7% | 5↑ 1↓ | $0.2B | 6.4% | 7 |
| Current FY 2026-12-31 |
$2.88 | $2.74 | $2.98 | 8.5% | +9.3% | 6↑ 1↓ | $0.8B | 5.5% | 7 |
| Next FY 2027-12-31 |
$3.64 | $3.18 | $4.01 | 26.6% | +3.8% | 6↑ 1↓ | $0.8B | 8.4% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.650 | |
| 7d ago | $0.620 | +0.030 |
| 30d ago | $0.708 | -0.057 |
| 60d ago | $0.688 | -0.038 |
| 90d ago | $0.848 | -0.197 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 1, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 1, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Barclays | INITIATE | — | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| May 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Apr 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Mar 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Feb 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% | |
| Jan 1, 2026 | 3 | 6 | 3 | 1 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
routine
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
<p>BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in it
May 27, 2026
other
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
<p align="center"><em>Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position</em></p>
May 20, 2026
activist
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
<p align="center"><em>Urges Stockholders to Vote “</em><strong><em>FOR</em></strong><em>” the Election of Pacira’s Highly Qualified Nominees on the </
May 20, 2026
Clinical Trial
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
Phase Phase 3 — COMPLETED
May 13, 2026
other
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
<p>BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver inno
May 12, 2026
activist
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
<p align="center"><em>Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals</em></p>
May 8, 2026
other
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, no
May 5, 2026
earnings
Pacira BioSciences Mails Letter to Stockholders
<p align="center"><em>Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results </em></p>
May 1, 2026
short_volume
Short Volume: PCRX — 61.4% short (0.5M / 0.8M)
Short: 520,520 | Exempt: 40 | TRF Vol: 848,056 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Pacira BioSciences Reports First Quarter 2026 Financial Results
<p align="center"><em>-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial po
Apr 30, 2026
earnings_calendar
PCRX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 28, 2026
other
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
<p align="center"><em>Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the </em><strong><em><u>BLUE</u></em></strong><em> Proxy
Apr 27, 2026
other
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- <pre>-- Findings show signi
Apr 13, 2026
fda
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
<p align="center"><strong><em>-- Select findings demonstrate that the use of EXPAREL</em></strong><sup><strong><em>®</em></strong></sup><strong><em> (
Apr 7, 2026
Clinical Trial
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Phase Phase 3 — COMPLETED
Mar 30, 2026
routine
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
<p align="center"><em>-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (
Mar 11, 2026
contract
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
<p align="center"><em>-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --</em></p> <p align="center"><em> -- No Shareholder